Affects Oracle E-Business Suite (widely used ERP). Remote, easily exploitable flaw allowing full takeover of a core enterprise application; broad impact across organizations.
CVE-2026-62534
Remote auth/privilege escalation in Oracle Applications Framework allowing full takeover (CVSS 8.8).
Is CVE-2026-62534 being exploited?
Not confirmed. CVE-2026-62534 does not appear in CISA's Known Exploited Vulnerabilities catalog, which records only exploitation that has been observed and reported publicly. That is evidence of absence of a report, not evidence the flaw is unattacked. EPSS currently estimates a 0.43% probability of exploitation in the next 30 days.
How severe is CVE-2026-62534?
CVE-2026-62534 is rated High with a CVSS score of 8.8. Severity describes how bad exploitation would be, not how likely it is: pair it with exploitation evidence before deciding what to patch first.
Is there a patch for CVE-2026-62534?
Yes. A fix has been recorded for CVE-2026-62534. The vendor advisory is the authority on the exact fixed version — apply it from there rather than from a summary.
What does CVE-2026-62534 affect?
CVE-2026-62534 affects Oracle Applications Framework (Web Utilities), Oracle E-Business Suite 12.2.11 - 12.2.15. Confirm the exact affected versions against the vendor advisory before deciding you are exposed.
What should I do about CVE-2026-62534?
Block/limit HTTP access to EBS, apply vendor patch when released, deploy WAF and increase monitoring.
Exploitation status reflects CISA's KEV catalog as we last synced it. Check the catalog directly.
Remote low‑privilege attacker via HTTP can escalate privileges/bypass auth and fully compromise Oracle Applications Framework (data theft, tampering, downtime).
Immediate action required
- affected>= 12.2.11 and <= 12.2.15
As published in the CVE Program record. A version outside these ranges is not a statement that it is unaffected — vendors sometimes understate a range, and distribution-backported builds carry upstream numbers that do not reflect what was patched into them.